Eli Lilly (LLY) stock soars after FDA approves Foundayo - can this weight-loss pill drive massive growth as investors bet big on obesity drug boom

Eli Lilly (LLY) stock today: Eli Lilly's stock surged over 5% following the US FDA's approval of its new oral weight-loss drug, Foundayo. This marks a significant expansion for Lilly in the lucrative obesity market. Clinical trials showed substantial weight loss, and the drug's accessible pricing strategy is expected to boost its adoption, strengthening Lilly's portfolio.